^
Association details:
Biomarker:PPFIBP2-BRAF fusion
Cancer:Melanoma
Drug:Yervoy (ipilimumab) (CTLA4 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion

Excerpt:
After four doses of ipilimumab, restaging showed progressive disease in both intra- and extra-cranial sites. A large brain metastasis was resected and an induction regimen of fotemustine was commenced, but by February 2014 the patient had developed progressive microcyticanemia and a CT scan demonstrated three new bowel metastases...At this time, in April2014, a PPFIBP2-BRAFfusion was discovered in DNA extracted from a resected brain metastasis...
DOI:
10.1111/pcmr.12388